Latest News
Web Date: December 6, 2017

Obsidian launches with $49.5 million to fine tune cellular and gene therapies

Tunable technology was born in the labs of Stanford professor Thomas Wandless
Department: Business
Keywords: Start-ups, Obsidian, T-cells, Michael Gilman

Armed with $49.5 million in its first formal round of funding, Obsidian Therapeutics has launched to fine tune the activity of cellular and gene therapies. Led by serial entrepreneur Michael Gilman, the Boston-based biotech firm aims to make the treatments safer and more effective across a broader range of diseases.

Ever since early clinical trials suggested chimeric antigen receptor (CAR) T cells could quickly obliterate blood cancer in some . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society